Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUN-101 (Glycopyrrolate) in COPD: GOLDEN-3
NCT02347761Phase 3Completed
- Sponsor
- Sunovion
- Start
- Feb 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycopyrrolate metered dose inhaler in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Sunovion. Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in 1 Second at 12 weeks. Started Feb 2015; status: completed.
02
Drugs
glycopyrrolate metered dose inhaler
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02347761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347761.